Jan. 27, 2004 — NanoCure Corp., an Ann Arbor, Mich., developer of a nanoscale therapeutic platform for cancer treatment, was awarded a contract from the Michigan Economic Development Corporation for $187,075 over three years, according to a news release.
null
The contract is part of $1.24 million awarded to the University of Michigan to develop a drug delivery platform based on dendrimer technology licensed by NanoCure from the university.
null
NanoCure’s portion of the award will support commercialization costs, such as developing applications for clinical testing and conducting clinical trials.